Clinical Study of Treatment of Allergia Rhinitis with Triamcinolone Acetonide Nasal Spray

OBJECTIVE:To investigate the clinical efficacy and safety of triamcinolone acetonide nasal spray treating allergia rhinitis, a multicentre, randomized control study with (beolomethasone dipropionate nasal spray) beconase was performed in 160 patients. METHODS:Dosage: triamcinolone acetonide nasal spray, 55μg/press and nasal spray, 2 presses one nostrile once, qd; beolomethasone dipropionate nasal spray, 50μg/press and nasal spray, 2presses one nostrile once, bid. The duration of treatment was 14 days in both groups. RESULTS:The clinical response of 100 cases in triamcinolone acetonide Nasal Spray and 60 in beolomethasone dipropionate nasal spray group were assessable. The overall clinical efficacy rates were 88% and 90%. The adverse drug reaction rates were 13% and 10% respectively. There were no signiticance between two groups (P0.05). CONCLUSION : Triamcinolone acetonide nasal spray is effective and safe in treatment of allergia rhinitis.